Ritonavir-PEG 8000 amorphous solid dispersions:: In vitro and in vivo evaluations

被引:149
|
作者
Law, D
Schmitt, EA
Marsh, KC
Everitt, EA
Wang, WL
Fort, JJ
Krill, SL
Qiu, YH
机构
[1] Abbott Labs, Global Pharmaceut Res & Dev, N Chicago, IL 60064 USA
[2] Wyeth Healthcare, Pharmaceut Res & Dev, Richmond, VA 23261 USA
[3] Boehringer Ingelheim Pharmaceut Inc, Pharmaceut Res & Dev, Ridgefield, CT 06877 USA
关键词
ritonavir; inhibition; cell lines; amorphous; solid dispersion; bioavailability; in vivo-in vitro correlation (IVIVC);
D O I
10.1002/jps.10566
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ritonavir is a large, lipophilic molecule that is practically insoluble in aqueous media and exhibits an exceedingly slow intrinsic dissolution rate. Although it has favorable lipophilicity, in vitro permeability studies have shown that ritonavir is a substrate of P-glycoprotein. Thus, the oral absorption of ritonavir could be limited by both dissolution and permeability, thereby making it a Class IV compound in the Biopharmaceutics Classification System. Because formulations rarely exert direct influence on local intestinal permeability, the effect of enhanced dissolution rate on oral absorption was explored. More specifically, poly(ethylene glycol) (PEG)-amorphous ritonavir solid dispersions were prepared with different drug loadings, and the in vitro and in vivo performances of the dispersions were evaluated. In vitro dissolution was conducted in 0.1N HCl with a USP Apparatus 1. A crossover design was used to evaluate the oral bioavailability of amorphous dispersions relative to crystalline drug in beagle dogs. Intrinsic dissolution measurements of the two solid phases indicated a 10-fold improvement in intrinsic dissolution rate for amorphous ritonavir compared with the crystalline counterpart. In vitro dissolution of ritonavir depended on the solid phase as well as drug loading of the dispersion. In vivo study results indicate that amorphous solid dispersions containing 10-30% drug exhibited significant increases in area under the curve of concentration versus time (AUC) and maximum concentration (C-max) over crystalline drug. For example, 10% amorphous dispersion exhibited increases of 22- and 13.7-fold in AUC and C-max respectively. However, both in vitro dissolution and bioavailability decreased with increasing drug load, which led to the construction of a multiple Level C in vitro-in vivo relationship for this Class IV compound. The established relationship between in vitro dissolution and in vivo absorption can help guide formulation development. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:563 / 570
页数:8
相关论文
共 50 条
  • [21] Amorphous solid dispersions of tegoprazan and three different polymers: In vitro/in vivo evaluation of physicochemical properties
    Kim, Paul
    Lee, In-Seo
    Kim, Ji-Yoon
    Lee, Min-Jeong
    Choi, Guang Jin
    KOREAN JOURNAL OF CHEMICAL ENGINEERING, 2023, 40 (04) : 986 - 998
  • [22] Amorphous solid dispersions of tegoprazan and three different polymers: In vitro/in vivo evaluation of physicochemical properties
    Paul Kim
    In-Seo Lee
    Ji-Yoon Kim
    Min-Jeong Lee
    Guang Jin Choi
    Korean Journal of Chemical Engineering, 2023, 40 : 986 - 998
  • [23] In vitro and in vivo performance of amorphous solid dispersions of ursolic acid as a function of polymer type and excipient addition
    Zhao, Tingting
    Gu, Chenming
    Qi, Jianbo
    Liu, Jingwen
    Wang, Yajun
    Chen, Xiaojing
    Guo, Fujiang
    Li, Yiming
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2024,
  • [24] Microencapsulation of amorphous solid dispersions of fenretinide enhances drug solubility and release from PLGA in vitro and in vivo
    Nieto, Kari
    Mallery, Susan R.
    Schwendeman, Steven P.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 586
  • [25] Influence of Copolymer Composition on In Vitro and In Vivo Performance of Celecoxib-PVP/VA Amorphous Solid Dispersions
    Knopp, Matthias Manne
    Julia Hoang Nguyen
    Mu, Huiling
    Langguth, Peter
    Rades, Thomas
    Holm, Rene
    AAPS JOURNAL, 2016, 18 (02): : 416 - 423
  • [26] Influence of Copolymer Composition on In Vitro and In Vivo Performance of Celecoxib-PVP/VA Amorphous Solid Dispersions
    Matthias Manne Knopp
    Julia Hoang Nguyen
    Huiling Mu
    Peter Langguth
    Thomas Rades
    René Holm
    The AAPS Journal, 2016, 18 : 416 - 423
  • [27] Design and Characterization of HY-038 Solid Dispersions via Spray Drying Technology: In Vitro and In Vivo Evaluations
    Jiang, Taotao
    Han, Limei
    Lu, Enhao
    He, Wenxiu
    Du, Shilin
    Sha, Xianyi
    AAPS PHARMSCITECH, 2021, 22 (08)
  • [28] Design and Characterization of HY-038 Solid Dispersions via Spray Drying Technology: In Vitro and In Vivo Evaluations
    Taotao Jiang
    Limei Han
    Enhao Lu
    Wenxiu He
    Shilin Du
    Xianyi Sha
    AAPS PharmSciTech, 22
  • [29] Enabling thermal processing of ritonavir-polyvinyl alcohol amorphous solid dispersions by KinetiSol® Dispersing
    LaFountaine, Justin S.
    Jermain, Scott V.
    Prasad, Leena Kumari
    Brough, Chris
    Miller, Dave A.
    Lubda, Dieter
    McGinity, James W.
    Williams, Robert O., III
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2016, 101 : 72 - 81
  • [30] In vitro-in vivo relationship for amorphous solid dispersions using a double membrane dissolution-permeation setup
    Jorgensen, Jacob Rune
    Mohr, Wolfgang
    Rischer, Matthias
    Sauer, Andreas
    Mistry, Shilpa
    Rades, Thomas
    Muellertz, Anette
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2023, 188 : 26 - 32